Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30 June in Geneva.
The company said five presentations will showcase its current and future approaches to migraine prevention, including new analyses for eptinezumab and primary phase 2b PROCEED data for the investigational treatment bocunebart.
Lundbeck said the eptinezumab presentations will explore patient‑centred outcomes in chronic migraine beyond traditional endpoints, including acute medication use, psychological well‑being and workplace productivity.
The company added that a late‑breaker presentation on bocunebart will provide further insight into PACAP pathway inhibition as a potential novel approach to migraine prevention in patients with prior preventive treatment failures.
Andrew Blumenfeld MD, Cedars Sinai Los Angeles and presenter of the PROCEED findings, said: “The presentation advances the evolving scientific understanding of PACAP pathway inhibition as a potential novel approach to migraine prevention for patients that continue to experience suboptimal disease control despite current preventive treatment options.”
Lundbeck will also present new analyses from the phase 3 SUNRISE and phase 4 RESOLUTION trials of eptinezumab. These will explore outcomes that reflect the wider clinical, functional and psychological burden of migraine.
Three RESOLUTION presentations will focus on adults with chronic migraine and medication‑overuse headache, examining outcomes across European countries, patterns of acute medication use over time and changes in symptoms of anxiety and depression.
The SUNRISE analysis will assess the impact of eptinezumab on workplace productivity and activity impairment across regions in Asia and Europe.
Johan Luthman, Executive Vice President and Head of Research & Development at Lundbeck, said: “The burden of migraine extends well beyond the number of headache days. For many people living with migraine, the disease can affect multiple aspects of daily life, yet these impacts are not always fully captured in traditional measures of treatment benefit.”
He added: “At EAN 2026, we are presenting data that reflect a broader view of migraine prevention, while also advancing scientific understanding of PACAP pathway inhibition through our investigational molecule bocunebart. Together, these presentations reflect Lundbeck’s commitment to advancing brain health in areas of unmet need.”
